As a journal specifically dedicated to bleeding disorders, it provides a focused platform for reporting advances in gene replacement therapy, factor IX and VIII gene delivery, and clinical outcomes in hemophilia patients. The gene discussed is F9; the disease is hemorrhagic disease.